Jade Biosciences(JBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

JBIO Jade Biosciences

交易中 08-24 13:21:44 EDT

21.13

-0.21

-0.98%

最高21.29	最低20.40	成交量32.07万
今开21.27	昨收21.34	日振幅4.19%
总市值13.44亿	流通市值9.96亿	总股本6,360万
成交额668.23万	换手率0.68%	流通股本4,712万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"JBIO","market":"US","secType":"STK","nameCN":"Jade Biosciences","latestPrice":21.13,"timestamp":1787592102773,"preClose":21.34,"halted":0,"volume":320655,"delay":0,"changeRate":-0.009840674789128437,"floatShares":47122000,"shares":63597387,"eps":-2.343303,"marketStatus":"交易中","change":-0.21,"latestTime":"08-24 13:21:44 EDT","open":21.27,"high":21.29,"low":20.395,"amount":6682332.8402700005,"amplitude":0.04194,"askPrice":21.16,"askSize":74,"bidPrice":21.12,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-2.343303,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1787601600000},"marketStatusCode":2,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":21.34,"postHourTrading":{"tag":"盘后","latestPrice":21.34,"preClose":21.34,"latestTime":"19:30 EDT","volume":9942,"amount":212162.1825,"timestamp":1787355006539,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.730246,"impliedVol":0.5972,"impliedVolPercentile":0.3426},"requestUrl":"/m/hq/s/JBIO","defaultTab":"news","newsList":[{"id":"1119067640","title":"Jade Biosciences 与 Paragon Therapeutics 达成全球独家授权协议 - 美国证券交易委员会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1119067640","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119067640?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:44","pubTimestamp":1783413872,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会的文件，Jade Biosciences公司已与Paragon Therapeutics签署了一项全球独家授权协议。\n根据协议条款，Jade Biosciences将向Paragon支付最高可达2200万美元的里程碑款项。此外，Jade Biosciences还需就授权产品的净销售额，向Paragon支付低至中个位数百分比的销售分成。\n该协议还包含一项为期至少五年的限制性条款，在此期间，Paragon被禁止针对协议授权的靶点发起新的研发活动。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172380379","title":"Jade Biosciences与Paragon达成协议：按授权产品净销售额支付低至中个位数百分比特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1172380379","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172380379?lang=zh_cn&edition=full","pubTime":"2026-07-02 05:10","pubTimestamp":1782940247,"startTime":"0","endTime":"0","summary":"根据提交给美国证券交易委员会（SEC）的文件，Jade Biosciences 已与Paragon公司达成一项特许权使用费协议。根据该协议，Jade Biosciences 将就其授权产品的净销售额，向Paragon支付低至中个位数百分比范围的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","JBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163004292","title":"Jade Biosciences 与 Paragon Therapeutics 签署全球独家许可协议 - SEC 文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1163004292","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163004292?lang=zh_cn&edition=full","pubTime":"2026-07-02 05:09","pubTimestamp":1782940151,"startTime":"0","endTime":"0","summary":"Jade Biosciences 已与 Paragon Therapeutics 达成一项全球独家许可协议，相关细节已通过美国证券交易委员会（SEC）的文件正式披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102837563","title":"新闻稿：Jade Biosciences宣布任命Mark Eisner医学博士、公共卫生硕士加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=1102837563","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102837563?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:02","pubTimestamp":1782471732,"startTime":"0","endTime":"0","summary":"旧金山与不列颠哥伦比亚省温哥华，2026年6月26日——专注于开发自身免疫性疾病领域最佳疗法的临床阶段生物技术公司Jade Biosciences, Inc.今日宣布，任命Mark Eisner医学博士、公共卫生硕士加入其董事会，自2026年6月25日起生效。Jade不承担也不接受任何公开更新或修订任何前瞻性陈述的义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163210976","title":"Jade Biosciences宣布首例受试者接受Jade201首次人体I期临床试验给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1163210976","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163210976?lang=zh_cn&edition=full","pubTime":"2026-05-27 04:06","pubTimestamp":1779825979,"startTime":"0","endTime":"0","summary":"Jade Biosciences宣布，其新型半衰期延长的无岩藻糖基化抗Baff受体单克隆抗体Jade201，已为首例受试者完成首次人体I期临床试验的首次给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","JBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125164700","title":"Jade Biosciences宣布首位受试者接受Jade101治疗IgA肾病的二期Juniper临床试验给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1125164700","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125164700?lang=zh_cn&edition=full","pubTime":"2026-05-26 19:02","pubTimestamp":1779793349,"startTime":"0","endTime":"0","summary":"Jade Biosciences宣布，其针对IgA肾病的候选药物Jade101，在二期Juniper临床试验中已为首位受试者完成给药。这一进展标志着该药物临床开发的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137369906","title":"Jade Biosciences注册声明：售股股东拟转售最多3954.2339万股普通股——美国证监会文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1137369906","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137369906?lang=zh_cn&edition=full","pubTime":"2026-05-08 05:22","pubTimestamp":1778188934,"startTime":"0","endTime":"0","summary":"根据最新向美国证券交易委员会（SEC）提交的文件显示，生物科技公司Jade Biosciences（股票代码：JBIO）已提交注册声明，该声明涉及售股股东计划转售的普通股股份。\n文件表明，此次注册声明涵盖的普通股数量最高可达39,542,339股。这些股份将由公司指定的售股股东进行二级市场转售操作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","JBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151902012","title":"玉生物科学任命爱德华·R·康纳博士为首席医疗官","url":"https://stock-news.laohu8.com/highlight/detail?id=1151902012","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151902012?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:05","pubTimestamp":1776855940,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司玉生物科学今日宣布，任命医学博士爱德华·R·康纳为公司首席医疗官，此项任命自即日起生效。康纳博士在加入玉生物科学之前，曾任职于Ardelyx公司，担任首席医疗官。玉生物科学是一家临床阶段的生物技术公司，专注于开发针对自身免疫性疾病关键未满足需求的同类最佳疗法。公司的领先候选药物JADE101靶向细胞因子APRIL，目前正在评估用于治疗免疫球蛋白A肾病。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JBIO","BK4022","BK4232","R","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618946801","title":"Jade Biosciences, Inc.盘中异动 早盘快速上涨5.68%报15.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618946801","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2618946801?lang=zh_cn&edition=full","pubTime":"2026-03-10 22:22","pubTimestamp":1773152551,"startTime":"0","endTime":"0","summary":"北京时间2026年03月10日22时22分，Jade Biosciences, Inc.股票出现波动，股价大幅拉升5.68%。Jade Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.37%。Jade Biosciences, Inc.公司简介：Jade Biosciences Inc专注于开发疗法，以解决自身免疫性疾病中尚未满足的关键需求。Jade是基于 Fairmount创立的抗体发现引擎Paragon Therapeutics许可的资产推出的。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310222232a6b5b7e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260310222232a6b5b7e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["JBIO","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135114107","title":"Jade Biosciences预计2026年中启动IgAN患者二期临床试验 初步数据有望2027年公布","url":"https://stock-news.laohu8.com/highlight/detail?id=1135114107","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135114107?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:05","pubTimestamp":1772798719,"startTime":"0","endTime":"0","summary":"Jade Biosciences宣布，公司计划于2026年中期启动针对IgA肾病（IgAN）患者的二期临床试验。根据最新规划，该项研究的初步数据预计将在2027年正式披露。\n此次临床试验的推进标志着公司在肾脏疾病治疗领域取得重要进展。通过二期试验，研究人员将深入评估候选药物的安全性与有效性，为后续临床开发提供关键依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106105650","title":"Jade Biosciences公司：截至2025年12月31日持有3.36亿美元现金及投资，预计资金可支撑运营至2028年上半年","url":"https://stock-news.laohu8.com/highlight/detail?id=1106105650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106105650?lang=zh_cn&edition=full","pubTime":"2026-03-06 20:03","pubTimestamp":1772798594,"startTime":"0","endTime":"0","summary":"截至2025年12月31日，Jade Biosciences公司持有的现金、现金等价物及投资总额达到3.36亿美元。这一资金规模预计将为公司提供充足的运营支持，使其能够持续开展研发与商业活动直至2028年上半年。\n充足的流动性为Jade Biosciences推进其生物科技管线提供了战略灵活性。公司管理层表示，现有资金将重点用于核心项目的临床研究和技术平台优化。财务储备的稳定性有助于降低短期融资需求带来的不确定性，为长期价值创造奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","JBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.jadebiosciences.com","stockEarnings":[{"period":"1week","weight":-0.1364},{"period":"1month","weight":0.0751},{"period":"3month","weight":-0.0392},{"period":"6month","weight":0.4954},{"period":"1year","weight":1.8916},{"period":"ytd","weight":0.383}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Jade Biosciences, Inc.最初于2018年7月27日作为特拉华州的Aerovate Therapeutics, Inc.注册成立。在2025年4月完成合并和注册地变更后，该公司现为内华达州公司，专注于为自身免疫性疾病患者开发新型生物疗法。其主要候选药物JADE101靶向APRIL用于治疗IgA肾病，另有针对BAFF-R及其他未披露通路的项目。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.072791},{"month":2,"riseRate":0.4,"avgChangeRate":-0.004913},{"month":3,"riseRate":0.6,"avgChangeRate":0.191335},{"month":4,"riseRate":0.4,"avgChangeRate":-0.148653},{"month":5,"riseRate":0,"avgChangeRate":-0.154925},{"month":6,"riseRate":0.8,"avgChangeRate":-0.02581},{"month":7,"riseRate":0.5,"avgChangeRate":-0.048527},{"month":8,"riseRate":0.666667,"avgChangeRate":0.061915},{"month":9,"riseRate":0.6,"avgChangeRate":0.018606},{"month":10,"riseRate":0.6,"avgChangeRate":0.005142},{"month":11,"riseRate":0.6,"avgChangeRate":0.137722},{"month":12,"riseRate":0.8,"avgChangeRate":0.213367}],"exchange":"NASDAQ","name":"Jade Biosciences","nameEN":"Jade Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Jade Biosciences(JBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Jade Biosciences(JBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Jade Biosciences,JBIO,Jade Biosciences股票,Jade Biosciences股票老虎,Jade Biosciences股票老虎国际,Jade Biosciences行情,Jade Biosciences股票行情,Jade Biosciences股价,Jade Biosciences股市,Jade Biosciences股票价格,Jade Biosciences股票交易,Jade Biosciences股票购买,Jade Biosciences股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Jade Biosciences(JBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Jade Biosciences(JBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}